GCM
RVMD icon

Greenland Capital Management’s Revolution Medicines RVMD Stock Holding History

Greenland Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
1,700
-2,300
-58% -$336K 0.04% 251
2026
Q1 		$389K Buy
+4,000
New +$404K 0.05% 209

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Greenland Capital Management's RVMD Position: Q2 2026 in Review

Greenland Capital Management increased its Revolution Medicines (RVMD) stake by 4.2% in Q2 2026, buying an estimated $83K and bringing the position to 14,000 shares worth $2.62M. The position accounts for 0.32% of the portfolio, ranked #64.

Greenland Capital Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Greenland Capital Management held 14,000 shares of Revolution Medicines worth $2.62M as of Q2 2026.
  • Greenland Capital Management bought 568 Revolution Medicines shares in Q2 2026, an estimated $83K.
  • Revolution Medicines made up 0.32% of Greenland Capital Management's portfolio in Q2 2026, its #64 holding.
  • Greenland Capital Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Greenland Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.